July 22, 2020 -- PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G (IgG) antibodies using its genetic screening processor (GSP)/dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) platforms.
Up to 5,000 samples of the fully automated kit can be processed per day, according to the company. PerkinElmer said that the finger-prick sample collection devices enable both decentralized sample collection and high-throughput testing.
In Europe, the kit is being marketed as a CE-IVD test. The firm plans to apply for an emergency use authorization with the U.S. Food and Drug Administration.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current